Post-Op Incentive Spirometry Not Beneficial After Bariatric Surgery

Share this content:
Post-Op Incentive Spirometry Not Beneficial After Bariatric Surgery
Post-Op Incentive Spirometry Not Beneficial After Bariatric Surgery

WEDNESDAY, Jan. 11, 2017 (HealthDay News) -- For patients undergoing bariatric surgery, postoperative incentive spirometry (IS) does not affect postoperative hypoxemia, arterial oxygen saturation, or postoperative pulmonary complications, according to a study published online Jan. 11 in JAMA Surgery.

Haddon Pantel, M.D., from the Lahey Hospital and Medical Center in Burlington, Mass., and colleagues conducted a randomized noninferiority trial involving 224 patients undergoing bariatric surgery. Patients were randomized to postoperative IS (control group; IS used 10 times every hour while awake) or clinical observation (test group).

The researchers observed no significant between-group differences in the frequency of postoperative hypoxemia at six, 12, or 24 postoperative hours (11.9 versus 10.4 percent [P= 0.72]; 5.4 versus 8.2 percent [P = 0.40], and 3.7 versus 4.6 percent [P = 0.73], respectively). The mean arterial oxygen saturation level did not differ significantly between the control and test groups at six, 12, or 24 postoperative hours (94.9 versus 94.9 percent [P = 0.99]; 95.4 versus 95.1 percent [P = 0.40]; and 95.7 versus 95.6 percent [P = 0.69], respectively). There was no significant difference observed between the groups in 30-day postoperative pulmonary complications (7.1 versus 3.6 percent [P = 0.24]).

"Based on these findings, the routine use of IS is not recommended after bariatric surgery in its current implementation," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »